Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Yuki Sato


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


Y. Sato, D. Fujimoto, K. Hosoya, K. Nagata, A. Nakagawa, R. Tachikawa, K. Tomii

Author affiliations

  • Respiratory Medicine, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3051


A better identification of patients who are more likely to benefit from immune checkpoint inhibitors is warranted in advanced non-small cell lung cancer (NSCLC). In resent preclinical study, obesity was associated with increased efficacy of PD-1/PD-L1 blockage. Herein, we conducted a retrospective study to investigate the prognostic accuracy of body mass index (BMI) and computed tomography-defined fat area in patients with advanced NSCLC treated with nivolumab.


We retrospectively analyzed patients with advanced NSCLC who received nivolumab at our institute between January 2016 and January 2019. Clinical data including BMI, visceral fat area (VFA) and subcutaneous fat area (SFA), and progression free survival (PFS) were collected. Treatment outcome of nivolumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.


In total, 126 patients were included in this study. High VFA (≥100cm2) were significantly associated with longer PFS, whereas high SFA (≥100cm2) and high BMI (≥25) were not. The objective response rates were higher in patients with high VFA than in those with low VFA (39% versus 19%; [P = 0.027], respectively). In multivariate analysis, high VSA (hazard ratio: 0.61, 95% confidence interval: 0.40–0.93; [P = 0.022]) and better PS (hazard ratio:0.35, 95% confidence interval: 0.19–0.68; [P = 0.003]) were identified as an independent predictor of longer PFS in patients treated with nivolumab.


In patients with advanced NSCLC who received nivolumab, high VFA were independent predictors of nivolumab efficacy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Kobe City Medical Center General Hospital.


Has not received any funding.


Y. Sato: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. D. Fujimoto: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. K. Hosoya: Speaker Bureau / Expert testimony: Ono Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.